Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience

Cui, Wanyuan; Yousaf, Nadia; Bhosle, Jaishree; Minchom, Anna; Nicholson, Andrew G.; Ahmed, Merina; McDonald, Fiona; Locke, Imogen; Lee, Richard W.; O’Brien, Mary; Popat, Sanjay

doi:10.1016/j.ctarc.2020.100261

Cited by 4 publications

(3 citation statements)

References 32 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most endangered population was patients with hematological malignancies, but it seems that close behind, patients with thoracic malignancies had one of the highest rates of mortality [ 9 ]. Patients with thoracic malignancies suffered from a longer and more severe course of COVID-19 because of their underlying illness, COPD and smoking damage to the lungs, resulting in 62–76% of hospitalizations and 25–33% of deaths directly attributed to COVID-19 [ 8 , 10 , 20 , 21 ]. Moreover, due to the unknown, cancer patients were reluctant to get vaccinated at first, fearing adverse events of vaccination, but also interaction with their oncological treatment and possible progression of disease [ 22 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes

Janzic,

Agbarya

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Due to the devastating COVID-19 pandemic, a preventive tool in the form of vaccination was introduced. Thoracic cancer patients had one of the highest rates of morbidity and mortality due to COVID-19 disease, but the lack of data about the safety and effectiveness of vaccines in this population triggered studies like ours to explore these parameters in a cancer population. Out of 98 patients with thoracic malignancies vaccinated per protocol, 60–75% experienced some adverse events (AE) after their first or second vaccination, most of them were mild and did not interfere with their daily activities. Out of 17 severe AEs reported, all but one were resolved shortly after vaccination. No significant differences were noted considering AE occurrence between different cancer therapies received after the first or second vaccination dose, p = 0.767 and p = 0.441, respectively. There were 37 breakthrough infections either after the first (1), second (13) or third (23) vaccine dose. One patient died as a direct consequence of COVID-19 infection and respiratory failure, and another after disease progression with simultaneous severe infection. Eight patients had moderate disease courses, received antiviral therapies and survived without consequences. Vaccination did not affect the time to disease progression or death from underlying cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes

Janzic,

Agbarya

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Since COVID-19 pandemics have had devastating consequences in the frail population of cancer patients, it is vital to gather as much reliable data as to demonstrate whether vaccination bene t this population. [2][3][4][5][6][7]9 Due to the paucity of data available, patients are often reluctant to be vaccinated since the e cacy and safety pro le of vaccines in this population is unknown, leaving them at low vaccination levels -from 40-60%. [19][20][21] From reports available so far, it is evident that patients with hematological malignancies do poorly in terms of seroconversion rates compared to patients treated for solid tumors.…”

Section: Discussionmentioning

confidence: 99%

“…1 Moreover, the COVID-19 pandemics has left devastating consequences in the cancer community with a late cancer diagnosis, deferred treatment decisions, and immense mortality rates among cancer patients reaching as high as 30%. [2][3][4][5][6][7] Furthermore, additional safety measures were incorporated such as telemedicine, and many patients' treatment was delayed due to the circumstances created by the pandemics. 8,9 Since COVID-19 disease adversely affects cancer patients, prophylactic strategies are crucial.…”

mentioning

confidence: 99%

Adequate Immunogenicity And Low Rate of Severe Adverse Events After SARS-CoV-2 mRNA-Based Vaccination In Patients With Solid Malignancies On Active Treatment Starts To Decline 3 Months After Complete Primary Course of Vaccination

Janžič

Bidovec‐Stojkovič

Mohorcic

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: SARS-CoV-2 vaccination in cancer patients is crucial since they are at increased risk of severe COVID-19 disease course, but data on efficacy and safety of vaccination are scarce.Methods: We performed a prospective observational study of patients with solid cancers on active anticancer treatment (chemotherapy, immunotherapy with immune checkpoint inhibitors (ICI) or targeted therapy) that received mRNA-based SARS-CoV-2 vaccination at two institutions in Slovenia. The immunogenicity was assessed by the detection of anti-SARS-CoV-2 S1 IgG antibodies in serum; patients were sampled before, 2-3 weeks after the first dose, 2-3 weeks after the second dose, and 3 months after the complete primary course of vaccination. The results were also compared to controls, sampled at similar time points.Results: Between March and July 2021 112 patients were included in the analysis. The seroconversion rate in patients without prior COVID-19 infection was 96% after the complete primary course of vaccination with 2 doses, compared to 100% for healthy controls. The seroconversion rate after vaccination for patients on chemotherapy, ICI, and targeted therapy was 100%, 91%, and 97%, respectively. All controls and the majority of patients on chemotherapy and targeted therapy, but only 83% for patients on ICI were adequate responders (anti-SARS-CoV-2 S1 IgG ≥ 880 ng/ml). Three months after the vaccination, a significant drop in antibody levels was observed in patients receiving ICI compared to controls (P < 0.001). Adverse events were mostly mild and predictable, none of the patients experienced serious adverse events after vaccination.Conclusions: Immunogenicity after mRNA-based vaccination against SARS-CoV-2 in cancer patients is only slightly impaired, but influenced by the type of anticancer therapy received. Patients on ICI have the slightest and gradual antibody production. Since antibody levels decline after three months, a third vaccination dose is reasonable to provide adequate protection against severe COVID-19 disease course.The study was approved by the National Ethics Committee (No. 0120-39/2021/6)

show abstract

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis

Tagliamento

Agostinetto

Bruzzone

et al. 2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience

Abstract: HIGHLIGHTS The immediate morbidity from COVID-19 is high in UK thoracic cancer patients Mortality, hospitalisation and treatment interruption rates were high All patients who died were current or ex-smokers

Cited by 4 publications

References 32 publications

Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes

Prospective Observational Study of COVID-19 Vaccination in Patients with Thoracic Malignancies: Adverse Events, Breakthrough Infections and Survival Outcomes

Adequate Immunogenicity And Low Rate of Severe Adverse Events After SARS-CoV-2 mRNA-Based Vaccination In Patients With Solid Malignancies On Active Treatment Starts To Decline 3 Months After Complete Primary Course of Vaccination

Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis

Contact Info

Product

Resources

About